Nicole Tully, MD
Family Medicine · Hoboken, NJNPI 1437337813
Payments from drug & device makers
Across 124 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$1K
- AbbVie$447
- Evofem Biosciences, Inc.$136
- E.r. Squibb & Sons, L.L.C.$125
- Pfizer$120
- Lilly USA, LLC$115
- plus $955 from 30 others
What the payments were for
- Speaking & faculty fees$1,27839%
- Food & beverage$1,92859%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 5 | $1,352 |
| AbbVie(2 entities) | 29 | $447 |
| Evofem Biosciences, Inc. | 10 | $136 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Pfizer | 7 | $120 |
| Lilly USA, LLC | 7 | $115 |
| Astellas Pharma US Inc | 4 | $84 |
| Mayne Pharma Commercial LLC | 5 | $68 |
| Exact Sciences | 4 | $67 |
| Avion Pharmaceuticals | 5 | $67 |
| Bausch Health US, LLC | 4 | $60 |
| Agile Therapeutics, Inc. | 4 | $57 |
| Merck | 4 | $51 |
| Lupin Inc. | 4 | $51 |
| Therapeuticsmd, Inc. | 3 | $46 |
| Novo Nordisk | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $36 |
| GSK | 2 | $32 |
| Scynexis, Inc. | 2 | $28 |
| Eisai Inc. | 2 | $24 |
| Avanos Medical | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Medicem Inc. | 1 | $15 |
| Sage Therapeutics, LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Duchesnay USA Incorporated | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
| Chiesi USA, Inc. | 1 | $13 |
| Organon | 1 | $13 |
| Coopersurgical, Inc. | 1 | $12 |
| Celularity Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,251 in reported general payments places this provider in the 80th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 43 | $713 |
| Alendronate Sodium | 32 | $320 |
| Levothyroxine Sodium | 37 | $262 |
| Metformin Hcl ErMetformin Hcl | 28 | $227 |
| Sertraline Hcl | 12 | $148 |
| Zolpidem Tartrate | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Hoboken
- Gaurang BrahmbhattHoboken$2.6M
- Gregory TraceyHoboken$181K
- Juan LatorreHoboken$71K
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.